🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

CanariaBio clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, India, South Korea, Spain, Italy, Belgium, Czechia, Canada, Brazil, Mexico and Taiwan registers with CanariaBio as lead sponsor. Synced 27 Sep 2026
4Current trials
0Recruiting now
8Drugs in these trials
11Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

CanariaBio is the lead sponsor of 4 current clinical trials in our USA, India, South Korea, Spain, Italy, Belgium, Czechia, Canada, Brazil, Mexico and Taiwan registers. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 2. The drugs named most often in its trials are Oregovomab, Carboplatin and Paclitaxel. The most-studied condition is Ovarian Cancer.

ClinicalTrials.gov trials by status

  • Active, closed4100%

Trials by phase

  • Phase 2250%
  • Phase 3125%
  • Phase 1/2125%
01

Clinical trials sponsored by CanariaBio

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
NCT05605535 · ClinicalTrials.gov ↗ · Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms
Phase 2 Active, closed 2023-02 India
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117 · ClinicalTrials.gov ↗ · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer
Phase 3 Active, closed 2020-08 USA, India, Spain, Italy, Belgium, Czechia, Canada, Brazil, Mexico, South Korea, Taiwan
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
NCT04938583 · ClinicalTrials.gov ↗ · Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV
Phase 1/2 Active, closed 2021-03 South Korea
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
NCT05335993 · ClinicalTrials.gov ↗ · Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer
Phase 2 Active, closed 2022-07 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in CanariaBio trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in CanariaBio trials

14 conditions
Ovarian Cancer2Carcinoma, Ovarian Epithelial1Ovarian Neoplasms1Ovarian Serous Adenocarcinoma1Recurrent Ovarian Cancer1Recurrent Epithelial Cancer of Ovary1Recurrent Epithelial Ovarian Cancer1Recurrent Fallopian Tube Cancer1Ovarian Neoplasm Epithelial1Fallopian Tube Neoplasms1Peritoneal Carcinoma1Ovarian Cancer by FIGO Stage1Ovarian Cancer Stage III1Ovarian Cancer Stage IV1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA20
Clinical trials in India20
Clinical trials in South Korea20
Clinical trials in Spain10
Clinical trials in Italy10
Clinical trials in Belgium10
Clinical trials in Czechia10
Clinical trials in Canada10
Clinical trials in Brazil10
Clinical trials in Mexico10
Clinical trials in Taiwan10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Ovarian Cancer

SponsorTrials
Fondazione Policlinico Universitario Agostino Gemelli IRCCS17
Tongji Hospital7
Verastem3
Xencor3
Anhui Provincial Cancer Hospital3
Hangzhou SynRx Therapeutics Biomedical Technology3
ARCAGY/ GINECO GROUP3
The Netherlands Cancer Institute2
Tubulis2
USWM CT2

Sponsors with the most current trials registered for this condition.

06

Questions about CanariaBio trials

How many clinical trials does CanariaBio sponsor?

CanariaBio is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA, India, South Korea, Spain, Italy, Belgium, Czechia, Canada, Brazil, Mexico and Taiwan registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are CanariaBio trials recruiting?

Not at the moment. None of its 4 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Which drugs is CanariaBio testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are Oregovomab (4), Carboplatin (3), Paclitaxel (3), Taxol (2) and Avastin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.